Jean Jacques Bienaime Purchases 7,000 Shares of Immunome, Inc. (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) Director Jean Jacques Bienaime purchased 7,000 shares of the stock in a transaction on Friday, August 16th. The stock was acquired at an average cost of $13.94 per share, for a total transaction of $97,580.00. Following the completion of the acquisition, the director now owns 16,615 shares of the company’s stock, valued at approximately $231,613.10. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Jean Jacques Bienaime also recently made the following trade(s):

• On Tuesday, May 21st, Jean Jacques Bienaime purchased 2,000 shares of Immunome stock. The stock was acquired at an average cost of $13.57 per share, for a total transaction of $27,140.00.

Immunome Stock Down 0.1 %

IMNM stock opened at $15.20 on Thursday. The company’s 50-day simple moving average is $13.52 and its 200-day simple moving average is $17.44. Immunome, Inc. has a 52-week low of $6.13 and a 52-week high of $30.96. The firm has a market cap of $911.53 million, a P/E ratio of -2.01 and a beta of 1.78.

Institutional Investors Weigh In On Immunome

Several hedge funds have recently modified their holdings of IMNM. Cerity Partners LLC purchased a new stake in shares of Immunome during the 4th quarter worth about $656,000. Jump Financial LLC purchased a new stake in shares of Immunome during the 4th quarter worth about $172,000. Mayo Clinic purchased a new stake in shares of Immunome during the 4th quarter worth about $1,161,000. Avidity Partners Management LP purchased a new stake in shares of Immunome during the 4th quarter worth about $14,268,000. Finally, Clear Creek Financial Management LLC purchased a new stake in shares of Immunome during the 1st quarter worth about $547,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

IMNM has been the topic of several recent research reports. Wedbush reaffirmed an “outperform” rating and issued a $33.00 price target on shares of Immunome in a report on Tuesday, August 13th. Piper Sandler lowered their price target on shares of Immunome from $27.00 to $23.00 and set an “overweight” rating on the stock in a report on Tuesday, August 13th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Immunome in a report on Tuesday, April 30th. They issued an “overweight” rating and a $24.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $29.00.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.